IDH-specific vaccine for high-grade gliomas
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas with specific IDH mutations. Here, Wolfgang Wick, MD, of the German Cancer ...
Author: VJOncology
Added: 06/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Astrocytoma | Brain Tumor | Cancer | Cancer & Oncology | Cancer Vaccines | Germany Health | Glioma | Vaccines